Zenas BioPharma, Inc. (ZBIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Zenas BioPharma, Inc. (ZBIO) closed at USD 24.86 on 2026-10-14, a change of -17.7 % over the past year, with a market capitalization of USD 1.66B.

Zenas BioPharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Zenas BioPharma, Inc. key figures

Previous close

USD 24.86 (2026-10-14)

1-year change

-17.7 %

Market cap

USD 1.66B

Enterprise value

USD 1.31B

P/E ratio (trailing)

-2.64

P/E ratio (forward)

-5.45

EPS (trailing)

-9.63

EPS (forward)

-4.66

PEG ratio

n/a

Price to book

6.51

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

18.11

Employees

167

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Zenas BioPharma, Inc. and compare it with other stocks.